Table 1. Patient demographics... | American Society of Hematology

Table 1.

Patient demographics

Characteristics	Dose level 1 100 million CAR-T (n = 6)	Dose level 2 300 million CAR-T (n = 6)
Age, y, median (min-max)	73 (66-75)	60 (53-65)
Sex	3 male	5 male
	3 female	1 female
BMPC >50%	3/6	4/6
Extramedullary disease	4/6	3/6
High-risk cytogenetics per IMWG	5/5∗	4/5∗
Prior lines of therapy, median (min-max)	5 (5-7)	4 (3-16)
Prior HSCT	3/6	4/6
Penta-refractory†	6/6	4/6
IgG myeloma	1	5
IgA myeloma	3	0
Light chain only	2	1

Characteristics	Dose level 1 100 million CAR-T (n = 6)	Dose level 2 300 million CAR-T (n = 6)
Age, y, median (min-max)	73 (66-75)	60 (53-65)
Sex	3 male	5 male
	3 female	1 female
BMPC >50%	3/6	4/6
Extramedullary disease	4/6	3/6
High-risk cytogenetics per IMWG	5/5∗	4/5∗
Prior lines of therapy, median (min-max)	5 (5-7)	4 (3-16)
Prior HSCT	3/6	4/6
Penta-refractory†	6/6	4/6
IgG myeloma	1	5
IgA myeloma	3	0
Light chain only	2	1

BMPC, bone marrow plasma cell; HSCT, hematopoietic stem cell transplant.

Some subjects were not evaluable or data were not available at time of data cutoff.

Penta-refractory patients are refractory to bortezomib, carfilzomib, daratumumab, lenalidomide, and pomalidomide.